New radiation combo may let some rectal cancer patients skip surgery

NCT ID NCT04677413

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new way of giving radiation therapy (ultra-fractionated, short course) along with standard chemotherapy for people with locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor enough to avoid surgery. The study will enroll 27 adults with stage T3-4 or node-positive rectal cancer who have not had prior treatment. The main focus is on safety and finding the highest dose that does not cause severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ultra-fractionated radiotherapy with FOLFOX or CAPOX chemotherapy
What this could lead to
If successful, this approach could allow some patients with advanced rectal cancer to avoid surgery by achieving a complete response with radiation and chemo alone.
What could go wrong
This is a very early phase 1 trial with only 27 participants, focused on safety and finding the right dose. It is not yet known if it will be effective or widely applicable, and there is a risk of serious gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UT Southwestern Medical Center

    Dallas, Texas, 75390-8849, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.